Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AVANOS MEDICAL, INC.HYH · Entity 28189 | President and CEO | May 03, 2017 | May 05, 2017 |
| AVIENT CORPAVNT · Entity 4061 | Director | September 30, 2026 | October 02, 2026 |
| HAEMONETICS CORPHAE · Entity 3953 | Director | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AVANOS MEDICAL, INC.
Report date May 03, 2017 · Filed May 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.74 · Expires 2027-05-03 | Direct | 134,680 |
Reported balance
After 2017-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-03 · Grant · Acquired 134,680 · Balance 134,680 F1: The awards vest 30% on May 3, 2018, 30% on May 3, 2019 and 40% on May 3, 2020, subject to earlier vesting in the event of death, disability or certain other events. |
Filing footnotes · ownership attribution and instrument terms
F1: The awards vest 30% on May 3, 2018, 30% on May 3, 2019 and 40% on May 3, 2020, subject to earlier vesting in the event of death, disability or certain other events.
AVIENT CORP
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,878 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 958 · Balance 42,878 |
HAEMONETICS CORP
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,519 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 2,538 · Balance 27,519 F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
F2: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 2, 2026 17:16 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 958 | $0.00 | $0.00 |
DisclosureSEC source: 0001122976-26-000132 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,878 Read SEC document |
| July 24, 2026 Filed Jul 28, 2026 20:49 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000313143-26-000099 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,519 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 15:34 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001122976-26-000108 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,920 Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 18:08 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001122976-26-000075 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,871 Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 18:10 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001122976-26-000002 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,799 Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 15:46 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,192 | $0.00 | $0.00 |
DisclosureSEC source: 0001122976-25-000071 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,560 Read SEC document |
| July 24, 2025 Filed Jul 25, 2025 20:18 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,693 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019591 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,981 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 17:59 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-018564 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,368 Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 19:23 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-011090 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,181 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 20:52 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 955 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000357 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,126 Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 20:13 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-024873 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,171 Read SEC document |
| July 25, 2024 Filed Jul 26, 2024 20:32 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,207 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-021040 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,288 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 19:58 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 806 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-019519 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,396 Read SEC document |
| March 29, 2024 Filed Apr 1, 2024 19:48 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 808 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011555 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,590 Read SEC document |
| December 31, 2023 Filed Jan 3, 2023 19:28 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-000091 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,244 Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 16:34 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 834 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-000239 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,782 Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:08 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 984 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-025145 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,948 Read SEC document |
| August 04, 2023 Filed Aug 8, 2023 20:27 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,226 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-022197 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,081 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 16:58 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 863 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-019842 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,964 Read SEC document |
| March 31, 2023 Filed Apr 3, 2023 19:46 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 857 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-011889 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,101 Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 17:57 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-023172 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,204 Read SEC document |
| August 05, 2022 Filed Aug 8, 2022 21:19 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-22-020695 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,855 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 18:13 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 880 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-018403 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,065 Read SEC document |
| March 31, 2022 Filed Apr 4, 2022 20:23 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 717 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-011164 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,185 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 18:15 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 627 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000041 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,468 Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:12 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 744 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-026279 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,841 Read SEC document |
| August 06, 2021 Filed Aug 9, 2021 23:10 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 3,077 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-023389 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,125 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 12:29 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 669 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-020887 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,097 Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 20:06 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 682 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-012578 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,428 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 17:24 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 804 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-000072 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,746 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 17:55 UTC | AVIENT CORP AVNT · Entity 4061 | GrantCommon Stock | 1,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-025972 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,942 Read SEC document |
| August 11, 2020 Filed Aug 12, 2020 22:04 UTC | HAEMONETICS CORP HAE · Entity 3953 | PurchaseCommon Stock | 4,000 | $80.93 | $323,720.00 |
DisclosureSEC source: 0001127602-20-023469 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,048 F1 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 21:11 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,983 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021973 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,048 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested RSUs previously reported. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 15:56 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-020539 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,740 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 23:18 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,705 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-012481 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,490 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 14:40 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 879 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-000324 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,785 Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 19:29 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-029357 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,906 Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 21:28 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,460 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-19-025262 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,065 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 13:18 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,055 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-023315 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,905 Read SEC document |
| March 31, 2019 Filed Apr 2, 2019 19:54 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-014076 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,850 Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:10 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 1,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-000658 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,742 Read SEC document |
| October 25, 2018 Filed Oct 26, 2018 20:18 UTC | AVIENT CORP POL · Entity 4061 | PurchaseCommon Stock | 10,000 | $30.64 | $306,422.00 |
DisclosureSEC source: 0001127602-18-031037 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,593 F1 · price: The purchase price is a weighted average for the purchase transactions. The purchase prices range from a low of $30.49 per share to a high of $30.72 per share. Full information regarding the number of shares purchased at each separate price is available upon request by the Commission staff, PolyOne Corporation, or a security holder of PolyOne Corporation. Read SEC document |
| September 30, 2018 Filed Oct 1, 2018 20:36 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 745 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-028774 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,593 Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 22:29 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 1,696 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-18-024065 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,605 F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2005 Long-Term Incentive Compensation Plan (as amended). The RSUs vest 100% on the first anniversary of the date of grant. F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. F3 · balance_after: This number includes unvested restricted stock units previously reported. Read SEC document |
| June 30, 2018 Filed Jul 2, 2018 20:20 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 660 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-022198 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 848 Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 21:02 UTC | AVIENT CORP POL · Entity 4061 | GrantCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-013769 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188 Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 20:42 UTC | HAEMONETICS CORP HAE · Entity 3953 | GrantCommon Stock | 2,909 | $45.30 | $131,763.16 |
DisclosureSEC source: 0001127602-17-030076 · form4.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,909 F1 · shares: Restricted Stock Unit grant which vests 100% on July 27, 2018. Grant was made under 2005 Long Term Incentive Compensation Plan Read SEC document |
| May 03, 2017 Filed May 5, 2017 20:29 UTC | AVANOS MEDICAL, INC. HYH · Entity 28189 | GrantEmployee Stock Option (right to buy) · Derivative | 134,680 | $0.00 Strike: $36.74 | $0.00 |
DisclosureSEC source: 0001606498-17-000029 · wf-form4_149401614597010.xml · derivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,680 Underlying: Common Stock · 134,680 shares Expires 2027-05-03 F1 · derivative.exercise_date: The awards vest 30% on May 3, 2018, 30% on May 3, 2019 and 40% on May 3, 2020, subject to earlier vesting in the event of death, disability or certain other events. Read SEC document |
| April 30, 2017 Filed May 3, 2017 22:45 UTC | AVANOS MEDICAL, INC. HYH · Entity 28189 | Tax withholdingCommon Stock | 18,366 | $39.50 | $725,457.00 |
DisclosureSEC source: 0001606498-17-000021 · wf-form4_149385153393354.xml · nonDerivative · entry 1 ABERNATHY ROBERT E · CIK 0001222888 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,677 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.